Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

145.04
Delayed Data
As of Feb 05
 -4.87 / -3.25%
Today’s Change
130.09
Today|||52-Week Range
181.81
-10.65%
Year-to-Date
Biogen Inc. Takes Aim at Johnson & Johnson
7:21am / MotleyFool.com
The Zacks Analyst Blog Highlights: Amazon.com, Microsoft, Visa, Skyworks Solutions an...
Jan 29 / Zacks.com
Rx for Success: Play Defense With Big Biotech
12:03am / TheStreet.com
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook
Jan 29 / Zacks.com
Amgen's Blincyto and Repatha Positive in Phase III Studies
Feb 05 / Zacks.com
Biotech ETF (IBB) Hits New 52-Week Low
Jan 29 / Zacks.com
Stocks Continue to Sink
Feb 05 / TheStreet.com
Amgen's Q4 Crushed Estimates and Answered 3 Important Questions in the Process
Jan 29 / MotleyFool.com
Borrowers return to eurozone bond markets
Feb 04 / FT.com
Q4 Pedal to the Metal: AMZN, MSFT, V & More
Jan 28 / Zacks.com
Will 2016 Be Amgen Inc.'s Best Year Yet?
Feb 03 / MotleyFool.com
Amgen (AMGN) Beats Q4 Earnings, Revenue Estimates
Jan 28 / Zacks.com
Why NantKwest Shares Fell 41% in January
Feb 02 / MotleyFool.com
Top Biotechs for 2016
Jan 28 / MotleyFool.com
Stocking Up on Cheap Biotech Stocks
Feb 02 / TheStreet.com
Stock Market News for January 28, 2016
Jan 28 / Zacks.com
3 Biotech Stocks You Don't Have to Babysit
Feb 01 / MotleyFool.com
Amgen's Biosimilar of AbbVie's Humira under FDA Review
Jan 27 / Zacks.com
3 Stocks Pulling The Drugs Industry Downward
Feb 01 / TheStreet.com
3 Healthcare Stocks You Don't Have to Babysit
Jan 27 / MotleyFool.com
Company News for February 01, 2016
Feb 01 / Zacks.com
3 Key Numbers to Monitor When Amgen Reports Fourth-Quarter Results
Jan 27 / MotleyFool.com
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Feb 01 / Zacks.com
Will Amgen (AMGN) Continue with the Earnings Streak in Q4?
Jan 26 / Zacks.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com
3 Reasons to Be Bearish on CVS Health
Jan 25 / MotleyFool.com
Biotech Billionaire Launches His Most Auspicious Project Yet
Jan 31 / MotleyFool.com
Amgen Presents Encouraging Phase III Data on Vectibix
Jan 25 / Zacks.com
AbbVie: There Ain't No Stinkin' Biosimilar Threat
Jan 30 / MotleyFool.com
Novartis (NVS) to Report Q4 Earnings: Will It Disappoint?
Jan 25 / Zacks.com
Where to Invest Money in 2016: 7 Great Ideas
Jan 30 / MotleyFool.com
Big pharma joins forces to tackle cancer
Jan 11 / FT.com
Stock Market News for January 29, 2016
Jan 29 / Zacks.com